Built from inside the operational gap
Jinwulei exists because biotech capital operations and fintech settlement rails have never shared a common language. We built the infrastructure that makes them speak.
Most fintechs see biotech as just another vertical
We came from inside biotech capital operations — reconciliation cycles, data-room due diligence, settlement failures at the fund boundary. That operational history is the design brief every product is measured against.
Capital efficiency is not a feature. It is the constraint we impose on ourselves: every architecture decision is weighed against cost-per-settlement and cost-per-data-event before it ships.
Hong Kong's dual framework is the moat
Hong Kong operates simultaneous regulatory regimes for financial services and life sciences — two bodies of law, one jurisdiction. That density is not a compliance overhead; it is the structural condition that makes a fintech-biotech bridge possible here and nowhere else.
We build in, not around, the SFC and HKMA frameworks. Regulatory rigor is the collateral — the asset that makes our data infrastructure credible to institutional counterparties.
The infrastructure layer-by-layer: how settlement rails connect to biotech data events, and what that means for your reconciliation overhead.